4-(2-aminoethyl)-3,5-difluoro-phenol | 751440-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-aminoethyl)-3,5-difluoro-phenol
• 英文别名: 4-(2-Aminoethyl)-3,5-difluorophenol
• CAS: 751440-47-8
• 化学式: C₈H₉F₂NO
• 分子量: 173.162
• InChiKey: RWSBYJCYOKCTOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(2,6-difluoro-4-methoxyphenyl)ethylamine hydrochloride 在 氢溴酸 作用下， 以 水 为溶剂， 反应 1.5h， 生成 4-(2-aminoethyl)-3,5-difluoro-phenol
  参考文献：
  名称：

  Structure–activity correlations for β-phenethylamines at human trace amine receptor 1

  摘要：

  A cell line in which RD-HGA16 cells were stably transfected with the hTAAR 1 receptor was created and utilized to carry out a systematic evaluation of a series of beta-phenethylamines. Fair agreement was observed with data obtained for aryl and ethylene chain substituted analogs in an AV12-664 cell line in which hemagglutinin-tagged hTAAR 1 was stably co-expressed with rat Gas. Analogs with multiple substituents as well as analogs with bulky groups were found to be partial agonists. Analogs in which the primary amino group was converted to a secondary or a tertiary amino group by N-methylation were also partial agonists. Comparative Molecular Field Analysis (CoMFA) using the potency data yielded a regression coefficient r(2) of 0.824. The steric field contribution to the model was 61% with the balance (39%) contributed by the electrostatic field. The collective results suggest that increasing steric bulk both at the amino nitrogen, particularly by N-dimethylation, and at the 4-position of the aromatic ring leads to low efficacy ligands. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.009

文献信息

• [EN] ASPARAGINE DERIVATIVES AND METHODS OF USING SAME<br/>[FR] DÉRIVÉS D'ASPARAGINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SENDA BIOSCIENCES INC

  公开号：WO2021252640A1

  公开（公告）日：2021-12-16

  The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

  本公开涉及式（A）和（I）的化合物，其药学上可接受的盐，以及任何上述化合物的溶剂化合物，包括相同的药物组合物，制备相同的方法，用于制备相同的中间化合物，以及使用相同的方法治疗或预防疾病，特别是癌症，如结直肠癌。